Fulgent Genetics Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromtoCommission File Number: 001-37894 FULGENT GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware(State or other jurisdiction ofincorporation or organization)4399 Santa Anita AvenueEl Monte, CA(Address of principal executive offices) (626) 350-0537 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☒Smaller reporting company☐Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of July 27, 2026, there were 27,515,293 outstanding shares of the registrant’s common stock. Table of Contents PART I—FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Comprehensive LossCondensed Consolidated Statements of Stockholders’ EquityCondensed Consolidated Statements of Cash FlowsNotes to the Condensed Consolidated Financial StatementsItem 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and ProceduresPART II—OTHER INFORMATIONItem 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales of Equity Securities and Use of ProceedsItem 5. Other InformationItem 6. ExhibitsExhibit IndexSignatures FULGENT GENETICS, INC.Condensed Consolidated Balance Sheets(in thousands, except par value data) The accompanying notes are an integral part of these condensed consolidated financial statements. FULGENT GENETICS, INC.Condensed Consolidated Statements of Cash Flows(in thousands)(unaudited) FULGENT GENETICS, INC.Notes to the Condensed Consolidated Financial Statements(unaudited) Note 1. Overview and Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principlesgenerally accepted in the United States, or U.S. GAAP, and presented in U.S. dollars, or USD, the reporting currency of the Company.These financial statements include the assets, liabilities, revenues and expenses of all subsidiaries and entities in which the Company hasa controlling financial interest or is deemed to be the primary beneficiary. In determining whether the Company is the primarybeneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct theeconomically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entitythat could potentially be significant to that entity. The Company uses the equity method to account for its investments in entities that itdoes not control, but in which it has the ability to exercise significant influence over operating and financial policies. All intercompanyaccounts and transactions are eliminated from the accompanying condensed consolidated financial statements. Nature of the Business Fulgent Genetics, Inc., together with its subsidiaries and affiliated professional corporations, or PCs (collectively referred to as theCompany, unless otherwise noted or the context requires otherwise), is a technology-based company with a well-established laboratoryservices business and a therapeutic development bus